Figure S5.
Panel A shows a heatmap with x-axis: cluster numbers and y-axis: CD95, CD28, CD26, CD56, KLRG1, NKp80, TIGIT, CD69, PD-1, CD57, and frequency. Marker expression patterns across TCR V delta 2 cell clusters are compared before and during treatment. Panel B shows flow cytometry plots. Left plots show x-axis: CD8 and y-axis: CD4. Middle plots show x-axis: TCR V gamma delta and y-axis: TCR alpha beta. Right plots show x-axis: CD3 and y-axis: CD56. Flow cytometry profiles of total T cells and double-negative T cells are compared between 2017 before treatment and 2025 under treatment.
Heatmap of t-SNE clusters from P1-derived TCR Vδ2 cells before and under baricitinib treatment. (A) Heatmap of clustering characterization of TCR Vδ2 cells from P1 before and under treatment with JAK inhibitor according to the expression of the CD95, CD28, CD26, CD56, KLRG1, NKp80, TIGIT, PD-1, and CD57. (B) Diagnostic laboratory-derived hemato-immunologic flow cytometry plots of T cells from P1 collected in 2017 (before baricitinib treatment) or in 2025 (under baricitinib treatment). Plots representing CD4 and CD8 expression on total T cells (left), followed by TCR γδ vs. TCR αβ (middle) and CD3 vs. CD56 (right) expression gated on CD4−CD8 DN cells. DN, double negative.